Biotech Startups

AFYX is a biopharmaceutical company focused on reformulation and repurposing of existing pharmaceuticals for conditions including head and neck cancer, labor induction, cluster headaches, and pain and addiction. The company operates across 46 global markets through direct operations and partnerships.

1 investor

AgTech Inventures is an agriculture technology innovation lab that develops intellectual property in agbiotech and precision agriculture, sourcing promising technologies from university research labs and small science-focused companies. It spins these technologies into new companies with input from industry partners, leading initial management teams and helping secure both non-dilutive and angel/venture financing.

1 investor

Agar Scientific manufactures laboratory platform rockers for gentle mixing applications in research and clinical settings. The company offers compact and full-sized models designed for continuous operation in benchtop and incubator environments.

1 investor

AgBiTech develops science-based biological insecticides using Baculovirus/NPV technology to control major crop pests, including insecticide-resistant worms, for row crop farmers. The company serves agricultural and regenerative farming markets with operations in Australia, Brazil, and the US.

1 investor

AGC Biologics is a contract development and manufacturing organization (CDMO) providing biopharmaceutical manufacturing services including cell therapy, mammalian, and mRNA-LNP production. The company operates multiple sites globally and is expanding its Japan capabilities with a new GMP-ready facility in Yokohama launching in 2027.

1 investor

AgelessRx offers prescription weight management medications delivered through a telehealth platform, including GLP-1 medications (semaglutide, tirzepatide), FDA-approved weight loss drugs (Wegovy, Zepbound), and supportive treatments like metformin and vitamin injections for adults seeking medically-supervised weight loss.

1 investor

Agemica uses AI to rank disease mechanisms across omics data, targets, and safe-drug libraries, then tests predicted drug combinations in ex-vivo human cancer models to measure cancer-cell death, tumor-volume reduction, and healthy-cell safety. The company advances the strongest candidates toward humanized-mouse studies, IND-enabling work, and clinical development in the AI drug discovery and oncology space.

1 investor

Agendia develops genomic technology and diagnostic tests for breast cancer patients. The company applies genomic science to improve treatment outcomes and quality of life for cancer patients.

1 investor

Agent Capital is a healthcare venture capital firm that makes direct equity investments in novel therapeutics and treatments across preclinical to commercial stages, focusing on addressing unmet patient needs. The firm partners with scientists and entrepreneurs to develop next-generation healthcare innovations.

1 investor

AgeRate develops science-based tools to measure biological aging, drawing on research in genetics and molecular epidemiology. The company aims to help people live healthier, longer lives.

1 investor

AgeRate develops science-based tools to measure biological age using genetics and molecular biomarkers, aimed at helping people improve health and longevity. The company builds on research in cardiovascular genetics, biochemistry, and bioinformatics.

1 investor

Aglaia is an investment firm specializing in early-stage oncology drug development companies, selecting and maturing breakthrough inventions with potential to transform cancer treatment. The firm has invested in 12 early-stage companies since 2004, six of which it founded, and has been involved in developing over 100 oncology products.

1 investor

Agno Pharmaceuticals is a US-headquartered contract development and manufacturing organization (CDMO) that produces regulatory starting materials, intermediates, active pharmaceutical ingredients, and drug formulations for pharmaceutical and biotech companies. The company operates FDA-inspected GMP-compliant facilities specializing in complex injectables, poorly soluble compounds, and highly potent APIs.

1 investor

Agrarius makes a crop treatment that activates plants' cellular defence mechanisms to promote deeper roots, better nutrient and water uptake, and resistance to pests, disease, and harsh conditions, while reducing fertilizer needs. It is sold to farmers for use on major crops and mixes into existing farm spraying systems.

1 investor

Agricen develops ACCOMPLISH MAX, a biocatalyst product that enhances nutrient availability in soil and increases crop stress tolerance, marketed for corn and other crops facing environmental challenges like drought and cold.

1 investor

Agrimax develops DK-20, an organic bio-based agricultural product derived from proprietary soil bacteria fermentation, designed to enhance crop yield and resilience for farmers globally. The product stimulates natural plant growth while improving nutrient uptake, disease resistance, and post-harvest quality across food and ornamental crops.

1 investor

Agrobiomics is a DTU spin-off developing biostimulants based on biomolecules produced by soil bacteria to help plants cope with abiotic stress. Its products, such as Pterica, are aimed at farmers and agricultural companies to reduce abiotic stress on crop yield and support more resilient, sustainable food production.

1 investor

Agronutris is a French biotechnology company that breeds and processes black soldier flies into proteins used for animal feed and soil nutrition. It operates as a mission-driven, B Corp-certified business focused on sustainable alternative protein sources.

1 investor

Agxio builds AI, data science and machine learning applications focused on the biotech, life sciences and agricultural science industries, addressing complex business problems for those sectors. The company operates a research hub in Cambridge and a development centre in Aberystwyth, Wales.

1 investor

Helical AI provides a virtual AI lab platform for drug discovery, tuning bio foundation models to a customer's own biology and orchestrating them into ranked, mechanistically grounded target and biomarker candidates. It is built for biopharma R&D teams, offering model-agnostic harnesses, therapeutically relevant benchmarking, and enterprise deployment without data lock-in.

1 investor

Aileens Pharma researches skin microbiome modulation and interkingdom communication to develop therapeutic applications. The company focuses on targeted skin microbiome technology for therapeutic use.

1 investor

AIM Biotech develops organ-on-chip and 3D tissue culture platforms (idenTx, organiX, and Avatar) for drug discovery and preclinical research. The company provides tools for academic and pharmaceutical researchers to model human tissue microenvironments and accelerate therapeutic development.

1 investor

ÄIO develops sustainable alternatives to animal fats and palm oil using proprietary microbial lipid technology for the oleochemical industry. The company converts agricultural and food industry side streams through fermentation-based biotechnology to produce ingredients for cosmetics and specialty chemicals.

1 investor

AIRA is a platform that uses AI to support clinical development decision-making and study design for pharmaceutical and biotech companies. The company addresses inefficiencies in the drug development process by providing a unified, regulatory-grade system to help clinical teams design therapies faster and more safely.

1 investor